Wegovy pill vs Foundayo: why GLP-1 treatment is becoming an ecosystem

What the source reports

GLP-1 treatment is no longer a market of broadly similar weekly injections. Once-daily Wegovy tablets and Foundayo are now approved in the United States, while weekly single- and dual-agonist injections remain established and triple-agonist medicines are advancing through trials.

At the same time, selected products have gained defined indications involving cardiovascular risk, chronic kidney disease, MASH and obstructive sleep apnoea. The result is better described as a treatment ecosystem than a single drug category.

That change makes a basic question more important: exactly which medicine, formulation, strength, schedule and approved purpose is being discussed? ‘GLP-1’ alone no longer supplies enough information.

Wegovy pill vs Foundayo: the short comparison

Wegovy tablets contain semaglutide, a peptide GLP-1 receptor agonist. The US maintenance dose for adults is 25 mg once daily after a staged dose escalation. It is the same active ingredient used in injectable Wegovy, but the tablet and injection have different strengths, administration instructions and schedules.

Foundayo is the brand name for orforglipron, a non-peptide small-molecule GLP-1 receptor agonist. It is also taken once daily after staged escalation, with a maximum labelled dose of 17.2 mg in the United States.

Comparing milligrams across the two products is meaningless: they are different molecules with different pharmacology and dosing systems. Neither tablet should be substituted for the other—or for an injection—without a prescribing decision.

The daily routines are not the same

The Wegovy tablet label says it should be taken in the morning on an empty stomach with up to four ounces of plain water, followed by at least 30 minutes before food, drink or other oral medicines. European guidance similarly specifies at least eight hours of fasting before the dose.

Foundayo can be taken with or without food. Its label says to swallow the tablet whole and not to break, crush or chew it. This removes oral semaglutide’s fasting window, but still creates a daily routine and a staged escalation schedule.

A daily pill may be easier for one person and harder for another. Convenience, adherence and tolerability are individual outcomes; route alone does not establish which medicine is preferable.

Weekly injections are not disappearing

Injectable Wegovy remains a once-weekly semaglutide product, while Zepbound is a once-weekly tirzepatide injection. Tirzepatide activates both GIP and GLP-1 receptors, so it is a dual agonist rather than a GLP-1-only medicine.

Weekly dosing can reduce the number of scheduled doses, while tablets avoid injections. Those are practical differences, not proof that one route produces better adherence, fewer side effects or better results for every person.

A person switching route may also move between different strengths, missed-dose rules or active ingredients. A medication history should preserve those changes rather than recording them as one uninterrupted entry called ‘GLP-1’.

Dual and triple agonists add another layer

The vocabulary is expanding alongside the formats. Semaglutide and orforglipron act through the GLP-1 receptor. Tirzepatide acts through GIP and GLP-1 receptors. Investigational retatrutide is designed to activate GIP, GLP-1 and glucagon receptors.

Retatrutide has reported Phase 3 results, but it remains investigational as of 7 August 2026. A triple mechanism and large company-reported weight-loss estimate do not make it approved, suitable for self-sourcing or automatically superior to authorised treatment.

Other programmes combine GLP-1 activity with amylin or glucagon pathways. These medicines may eventually broaden treatment choices, but different mechanisms can also bring different dose schedules, adverse effects, contraindications and evidence gaps.

Approved purpose now matters as much as product name

A familiar active ingredient can have several product-specific uses. In the United States, Wegovy injection and tablets include weight management and defined cardiovascular-risk reduction indications. Foundayo’s initial approval is for long-term weight reduction in defined adults, not cardiovascular-risk reduction.

Ozempic, another semaglutide product, has indications for type 2 diabetes and defined cardiovascular and kidney outcomes in adults with type 2 diabetes and chronic kidney disease. Zepbound has a defined indication for moderate-to-severe obstructive sleep apnoea in adults with obesity.

Wegovy injection also has accelerated US approval for adults with MASH and moderate-to-advanced fibrosis. These indications cannot be transferred automatically between brands, formulations, countries or every medicine with GLP-1 activity.

Adherence now means more than remembering an injection

Useful adherence information can include the exact active ingredient and brand, tablet or injection, prescribed strength, daily or weekly schedule, dose-escalation stage, fasting instructions, missed doses, treatment gaps and start or stop dates.

Side-effect records need timing as well as a symptom name. Nausea occurring during escalation, reduced drinking during gastrointestinal illness or a symptom arising after a product switch provide different context from an undated list.

A reminder can support the prescribed routine, but it should not calculate an unapproved conversion, advise a dose change or decide whether a missed dose should be replaced. Those rules differ by product and belong to the current label and prescribing team.

Weight is only one part of the record

Large GLP-1 trials and a recent New England Journal of Medicine review have renewed attention to lean-mass loss, physical function and what happens after treatment stops. Weight alone cannot show whether a person is maintaining strength, eating adequately or feeling well.

Protein intake, hydration, resistance exercise, side effects, sleep and day-to-day function can therefore be useful topics to record and discuss. They should not be converted into universal targets because needs vary with age, health conditions, treatment and professional advice.

Trends can improve recall and support a better appointment. They cannot prove that a medicine caused a change, measure muscle accurately without an appropriate assessment or replace investigation of concerning symptoms.

What remains uncertain

It is too early to know how oral and injectable market share will settle, how long people will continue each treatment or whether fewer administration restrictions will produce better real-world adherence.

Access will differ by country, supply, price and reimbursement. US or EU approval does not mean a medicine is available everywhere, and product names or authorised uses can vary between markets.

Several multi-agonists still need full publication, regulatory review and longer-term safety evidence. More mechanisms and higher cross-trial weight-loss percentages do not establish a universal ranking.

What this means for OurGLP1 users

The useful role for an app is not to choose a treatment. It is to preserve an accurate, understandable history across changing medicines, formats and routines, and to help the individual decide what information is worth taking to a clinician.

That history should remain editable by the user and distinguish recorded facts from app-generated observations. A pattern involving weight, appetite, hydration, sleep or side effects can prompt a question without becoming a diagnosis or dosing instruction.

As the ecosystem grows, the individual becomes more—not less—important. Two people taking medicines described casually as ‘GLP-1s’ may be using different molecules for different reasons, on different schedules, with different experiences.

Bottom line

Wegovy tablets and Foundayo show why the next phase of GLP-1 treatment is about more than replacing injections with pills. They are separate once-daily medicines with different active ingredients and administration routines, while weekly injections, dual agonists and investigational triple agonists continue alongside them.

The practical challenge is clarity: medicine, formulation, schedule, indication and individual response all matter. That is the opportunity for OurGLP1—helping people keep a reliable record and prepare better questions without turning tracking into medical advice.